Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 4, 2015, Pages 749-758

  Gabbert, Tatjana I ^a   Hoffmeister, Bodo ^a   Felsenberg, Dieter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bisphosphonates; Cancer; Germany; Ibandronate; Kidney; Osteonecrosis of the jaw

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG INDICATION; FEMALE; HUMAN; JAW OSTEONECROSIS; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; SEX DIFFERENCE; SURVIVAL TIME; BREAST NEOPLASMS; CHEMICALLY INDUCED; GERMANY; HEMATOLOGIC NEOPLASMS; JAW DISEASES; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MIDDLE AGED; NEOPLASMS; OSTEONECROSIS; PROSTATIC NEOPLASMS; REGISTER; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TIME;

AGED; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HEMATOLOGIC NEOPLASMS; HUMANS; IMIDAZOLES; JAW DISEASES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS; OSTEONECROSIS; PROSTATIC NEOPLASMS; REGISTRIES; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 84925493219     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1853-6     Document Type: Article

References (30)

1. Bamias A et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587. doi:10.1200/JCO.2005.02.8670
2. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44:857–869
3. Cartsos VM, Zhu S, Zavras AI (2008) Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 139:23–30
4. Clines GA, Guise TA (2004) Mechanisms and treatment for bone metastases. Clin Adv Hematol Oncol 2:295–302
5. Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21:1545–1548
6. EU Law Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010. http://ec.europa.eu/health/files/eudralex/vol-1/dir_2010_84/dir_2010_84_en.pdf. http://ec.europa.eu/health/files/eudralex/vol-1/dir_2010_84/dir_2010_84_en.pdf. Accessed 27 June 2014
7. Dodson TB (2009) Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67:44–52. doi:10.1016/j.joms.2008.12.004
8. Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99–102 discussion 199–102
9. Ebetino FH et al (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49:20–33. doi:10.1016/j.bone.2011.03.774
10. FDA (2014) US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed 09 September 2014
11. Federal Statistical Office. German Statistical Yearbook 2014. https://www.destatis.de. Accessed 03 July 2014
12. Felsenberg D, Lopez S, Gabbert T, Hoffmeister B (2012) Osteonecrosis of the jaw in patients with osteoporosis. Osteologie 21:207–212
13. Hadji P, Gnant M, Aapro M, Lipton A, Coleman R (2011) Dosing of zoledronic acid throughout the treatment continuum in breast cancer. Crit Rev Oncol Hematol 79:175–188. doi:10.1016/j.critrevonc.2010.07.017
14. Hoff AO et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826–836. doi:10.1359/jbmr.080205
15. Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF (2011) Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann NY Acad Sci 1218:47–54. doi:10.1111/j.1749-6632.2010.05771.x
16. Hoffmann F, Jung TI, Felsenberg D, Glaeske G (2008) Pattern of intravenous bisphosphonate use in outpatient care in Germany. Pharmacoepidemiol Drug Saf 17:896–903. doi:10.1002/pds.1634
17. Jadu F, Lee L, Pharoah M, Reece D, Wang L (2007) A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 18:2015–2019. doi:10.1093/annonc/mdm370
18. Jung TI, Hoffmann F, Glaeske G, Felsenberg D (2010) Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy. J Cancer Res Clin Oncol 136:363–370. doi:10.1007/s00432-009-0662-9
19. Kruger TB, Sharikabad MN, Herlofson BB (2013) Bisphosphonate-related osteonecrosis of the jaw in four Nordic countries and an indication of under-reporting. Acta Odontol Scand 71:1386–1390. doi:10.3109/00016357.2013.764007
20. McKay RR, Lin X, Perkins JJ, Heng DY, Simantov R, Choueiri TK (2014) Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma. Eur Urol. doi:10.1016/j.eururo.2014.02.040
21. Rote Liste Rote Liste Service GmbH. www.rote-liste.de. Accessed 27 June 2014
22. Rugani P, Luschin G, Jakse N, Kirnbauer B, Lang U, Acham S (2014) Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer. Clin Oral Invest 18:401–407. doi:10.1007/s00784-013-1012-5
23. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67:2–12. doi:10.1016/j.joms.2009.01.009
24. Scher HI, Motzer RJ (2005) Bladder and renal cell carcinomas. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds) Harrison’s principles of internal medicine, vol I, 16th edn. McGraw-Hill Companies, New York, pp 541–543
25. Shapiro CL (2013) Bisphosphonate-related osteonecrosis of jaw in the adjuvant breast cancer setting: risks and perspective. J Clin Oncol 31:2648–2650. doi:10.1200/JCO.2013.48.6837
26. Sharma D et al. (2013) Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect Vascular cell 5:1 doi:10.1186/2045-824X-5-1
27. Ulmner M, Jarnbring F, Torring O (2014) Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg 72:76–82. doi:10.1016/j.joms.2013.06.221
28. Walter C et al (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54:1066–1072. doi:10.1016/j.eururo.2008.06.070
29. Wessel JH, Dodson TB, Zavras AI (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66:625–631. doi:10.1016/j.joms.2007.11.032
30. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS (2007) Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 99:1016–1024